Skip to content

Effectiveness of Hijama with Roghan e Baboona in the treatmentof low back pain

A Randomized Controlled Trial to Assess the Effectiveness of Hijamah bila Shart with Roghan e Baboona in Non specific low back pain and its potential role in improving the Quality of Life in Majeedia Unani Hospital South East Delhi - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075309
Enrollment
80
Registered
2024-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M629- Disorder of muscle, unspecified

Interventions

Intervention1: Hijamah-Bila-Shart therapy with Roghan-e-Baboona: Duration of Therapy-15 minutes Total Sittings-7 Patients will receive hijama therapy on alternate days for two weeks and will be evalua

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of low back pain 2.Oswestry low back pain score up to 24 (mild to moderate disability) 3.willing to take Hijama therapy with Roghan-e-Baboona in experimental group 4. Willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Any previous spine surgery 2. Acute injury of Lumbosacral region 3. Patients with any specific causes of low back pain e.g., Vertebral fracture, herniated disc in the lumbar region, Spinal infections and spinal tumor 4. Major medical illness under treatment 5. Radiological investigation suggestive of any lower back pathology 6.Pregnant women 7. Patients with known skin disorders 8. Patients not in a condition to give valid consent 9. Not willing to participate in the study

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale Oswestry Low back Disability QuestionnaireTimepoint: At baseline at 14 Day (After completion of therapy) and at 21 Day (After one week of treatment free period)

Secondary

MeasureTime frame
SF12V2 Quality of Life QuestionnaireTimepoint: At baseline, after completion of therapy at 14 Day and after one week of treatment free period at day 21

Countries

India

Contacts

Public ContactDr Farkhunda Jabin

Jamia Hamdard New Delhi

mousman2010@gmail.com8979968072

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026